Sutro Biopharma (STRO) Non-Current Debt (2018 - 2022)

Sutro Biopharma has reported Non-Current Debt for 5 years, with the latest figure at $3.8 million in Q4 2022.

• Quarterly Non-Current Debt fell 76.04% year-over-year to $3.8 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $3.8 million (down 76.04% YoY) and the FY2022 annual result came in at $3.8 million, down 76.04% from the prior year.
• Non-Current Debt slipped to $3.8 million in Q4 2022 per STRO's latest filing, from $6.8 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $24.7 million in Q1 2021 and troughed at $3.8 million in Q4 2022.
• A 5-year average of $14.6 million and a median of $12.1 million in 2018 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2020 and 2022: Non-Current Debt surged 343.84% in 2020, then plunged 76.04% in 2022.
• Over 5 years, Non-Current Debt stood at $10.0 million in 2018, then declined by 11.24% to $8.9 million in 2019, then surged by 176.53% to $24.5 million in 2020, then tumbled by 35.88% to $15.7 million in 2021, then slumped by 76.04% to $3.8 million in 2022.
• According to Business Quant data, Non-Current Debt over the past three periods registered $3.8 million, $6.8 million, and $9.8 million for Q4 2022, Q3 2022, and Q2 2022 respectively.